In the phase III KEYNOTE-061 trial for patients with previously treated G/GEJ adenocarcinoma with a PD-L1 CPS ≥ 1, pembrolizumab did not significantly improve the median OS compared with paclitaxel (9.1 vs. 8.3 months, hazard ratio [HR]: 0.82, 95% CI: 0.66–1.03, p = 0.0421). This evidence concerns the gene CD274 and adenocarcinoma.